{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:55:54Z","timestamp":1778676954512,"version":"3.51.4"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Biomed Eng"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10439-011-0280-y","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T20:52:51Z","timestamp":1298580771000},"page":"1235-1251","source":"Crossref","is-referenced-by-count":21,"title":["Intracellular Trafficking Considerations in the Development of Natural Ligand-Drug Molecular Conjugates for Cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Dennis J.","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina T.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin S.","family":"Quinlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parsa M.","family":"Nafisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel T.","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,25]]},"reference":[{"key":"280_CR1","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0021-9258(19)62337-9","volume":"253","author":"P Aisen","year":"1978","unstructured":"Aisen, P., A. Leibman, and J. Zweier. Stoichiometric and site characteristics of the binding of iron to human transferrin. J. Biol. Chem. 253:1930\u20131937, 1978.","journal-title":"J. Biol. Chem."},{"key":"280_CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1139\/o01-153","volume":"80","author":"EN Baker","year":"2002","unstructured":"Baker, E. N., H. M. Baker, and R. D. Kidd. Lactoferrin and transferrin: functional variations on a common structural framework. Biochem. Cell Biol. 80:27\u201334, 2002.","journal-title":"Biochem. Cell Biol."},{"key":"280_CR3","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1016\/S0021-9258(19)50442-2","volume":"267","author":"K Barabas","year":"1992","unstructured":"Barabas, K., J. A. Sizensky, and W. P. Faulk. Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA. J. Biol. Chem. 267:9437\u20139442, 1992.","journal-title":"J. Biol. Chem."},{"key":"280_CR4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0304-4157(93)90002-6","volume":"1154","author":"L Barbieri","year":"1993","unstructured":"Barbieri, L., M. G. Battelli, and F. Stirpe. Ribosome-inactivating proteins from plants. Biochim. Biophys. Acta 1154:237\u2013282, 1993.","journal-title":"Biochim. Biophys. Acta"},{"key":"280_CR5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0092-8674(80)90540-1","volume":"22","author":"D Barnes","year":"1980","unstructured":"Barnes, D., and G. Sato. Serum-free cell culture: a unifying approach. Cell 22:649\u2013655, 1980.","journal-title":"Cell"},{"key":"280_CR6","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","volume":"91","author":"RH Bobo","year":"1994","unstructured":"Bobo, R. H., D. W. Laske, A. Akbasak, P. F. Morrison, R. L. Dedrick, and E. H. Oldfield. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA 91:2076\u20132080, 1994.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"280_CR7","first-page":"2665","volume":"20","author":"B Bodey","year":"2000","unstructured":"Bodey, B., B. Bodey, Jr., S. E. Siegel, and H. E. Kaiser. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 20:2665\u20132676, 2000.","journal-title":"Anticancer Res."},{"key":"280_CR8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1096\/fj.01-0521com","volume":"16","author":"M Brigotti","year":"2002","unstructured":"Brigotti, M., R. Alfieri, P. Sestili, M. Bonelli, P. G. Petronini, A. Guidarelli, L. Barbieri, F. Stirpe, and S. Sperti. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. Faseb J. 16:365\u2013372, 2002.","journal-title":"Faseb J."},{"key":"280_CR9","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1091\/mbc.12.6.1897","volume":"12","author":"P Burke","year":"2001","unstructured":"Burke, P., K. Schooler, and H. S. Wiley. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell 12:1897\u20131910, 2001.","journal-title":"Mol. Biol. Cell"},{"key":"280_CR10","doi-asserted-by":"crossref","first-page":"20021","DOI":"10.1073\/pnas.1008261107","volume":"107","author":"M Candolfi","year":"2010","unstructured":"Candolfi, M., W. Xiong, K. Yagiz, C. Liu, A. K. Muhammad, M. Puntel, D. Foulad, A. Zadmehr, G. E. Ahlzadeh, K. M. Kroeger, M. Tesarfreund, S. Lee, W. Debinski, D. Sareen, C. N. Svendsen, R. Rodriguez, P. R. Lowenstein, and M. G. Castro. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc. Natl Acad. Sci. USA 107:20021\u201320026, 2010.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"280_CR11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/annonc\/mdh257","volume":"15","author":"L Castillo","year":"2004","unstructured":"Castillo, L., M. C. Etienne-Grimaldi, J. L. Fischel, P. Formento, N. Magne, and G. Milano. Pharmacological background of EGFR targeting. Ann. Oncol. 15:1007\u20131012, 2004.","journal-title":"Ann. Oncol."},{"key":"280_CR12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0092-8674(80)90366-9","volume":"22","author":"DB Cawley","year":"1980","unstructured":"Cawley, D. B., H. R. Herschman, D. G. Gilliland, and R. J. Collier. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell 22:563\u2013570, 1980.","journal-title":"Cell"},{"key":"280_CR13","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.V75.10.1903.1903","volume":"75","author":"M Cazzola","year":"1990","unstructured":"Cazzola, M., G. Bergamaschi, L. Dezza, and P. Arosio. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 75:1903\u20131919, 1990.","journal-title":"Blood"},{"key":"280_CR14","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1073\/pnas.84.13.4538","volume":"84","author":"VK Chaudhary","year":"1987","unstructured":"Chaudhary, V. K., D. J. FitzGerald, S. Adhya, and I. Pastan. Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc. Natl. Acad. Sci. USA 84:4538\u20134542, 1987.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"280_CR15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/BF00571645","volume":"7","author":"DC Chen","year":"1982","unstructured":"Chen, D. C., B. Newman, R. M. Turkall, and M. F. Tsan. Transferrin receptors and gallium-67 uptake in vitro. Eur. J. Nucl. Med. 7:536\u2013540, 1982.","journal-title":"Eur. J. Nucl. Med."},{"key":"280_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08830189809084486","volume":"17","author":"P Chomarat","year":"1998","unstructured":"Chomarat, P., and J. Banchereau. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int. Rev. Immunol. 17:1\u201352, 1998.","journal-title":"Int. Rev. Immunol."},{"key":"280_CR17","doi-asserted-by":"crossref","first-page":"9681","DOI":"10.1016\/S0021-9258(17)44551-0","volume":"258","author":"A Ciechanover","year":"1983","unstructured":"Ciechanover, A., A. L. Schwartz, A. Dautry-Varsat, and H. F. Lodish. Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J. Biol. Chem. 258:9681\u20139689, 1983.","journal-title":"J. Biol. Chem."},{"key":"280_CR18","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.4049\/jimmunol.176.12.7495","volume":"176","author":"MO Daines","year":"2006","unstructured":"Daines, M. O., Y. Tabata, B. A. Walker, W. Chen, M. R. Warrier, S. Basu, and G. K. Hershey. Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling. J. Immunol. 176:7495\u20137501, 2006.","journal-title":"J. Immunol."},{"key":"280_CR19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","volume":"464","author":"ME Davis","year":"2010","unstructured":"Davis, M. E., J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, and A. Ribas. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067\u20131070, 2010.","journal-title":"Nature"},{"key":"280_CR20","doi-asserted-by":"crossref","first-page":"16775","DOI":"10.1074\/jbc.270.28.16775","volume":"270","author":"W Debinski","year":"1995","unstructured":"Debinski, W., N. I. Obiri, I. Pastan, and R. K. Puri. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 270:16775\u201316780, 1995.","journal-title":"J. Biol. Chem."},{"key":"280_CR21","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.1021\/bi00096a004","volume":"32","author":"JC Dewan","year":"1993","unstructured":"Dewan, J. C., B. Mikami, M. Hirose, and J. C. Sacchettini. Structural evidence for a pH-sensitive dilysine trigger in the hen ovotransferrin N-lobe: implications for transferrin iron release. Biochemistry 32:11963\u201311968, 1993.","journal-title":"Biochemistry"},{"key":"280_CR22","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.4049\/jimmunol.161.5.2317","volume":"161","author":"DD Donaldson","year":"1998","unstructured":"Donaldson, D. D., M. J. Whitters, L. J. Fitz, T. Y. Neben, H. Finnerty, S. L. Henderson, R. M. O\u2019Hara, Jr., D. R. Beier, K. J. Turner, C. R. Wood, and M. Collins. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J. Immunol. 161:2317\u20132324, 1998.","journal-title":"J. Immunol."},{"key":"280_CR23","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","volume":"56","author":"H Elnakat","year":"2004","unstructured":"Elnakat, H., and M. Ratnam. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 56:1067\u20131084, 2004.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"280_CR24","doi-asserted-by":"crossref","first-page":"15749","DOI":"10.1016\/S0021-9258(17)40744-7","volume":"269","author":"AR French","year":"1994","unstructured":"French, A. R., G. P. Sudlow, H. S. Wiley, and D. A. Lauffenburger. Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. J. Biol. Chem. 269:15749\u201315755, 1994.","journal-title":"J. Biol. Chem."},{"key":"280_CR25","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1074\/jbc.270.9.4334","volume":"270","author":"AR French","year":"1995","unstructured":"French, A. R., D. K. Tadaki, S. K. Niyogi, and D. A. Lauffenburger. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor\/ligand interaction. J. Biol. Chem. 270:4334\u20134340, 1995.","journal-title":"J. Biol. Chem."},{"key":"280_CR26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0006-2952(95)02225-2","volume":"51","author":"M Fritzer","year":"1996","unstructured":"Fritzer, M., T. Szekeres, V. Szuts, H. N. Jarayam, and H. Goldenberg. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. Biochem. Pharmacol. 51:489\u2013493, 1996.","journal-title":"Biochem. Pharmacol."},{"key":"280_CR27","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.str.2005.07.016","volume":"13","author":"AM Giannetti","year":"2005","unstructured":"Giannetti, A. M., P. J. Halbrooks, A. B. Mason, T. M. Vogt, C. A. Enns, and P. J. Bjorkman. The molecular mechanism for receptor-stimulated iron release from the plasma iron transport protein transferrin. Structure 13:1613\u20131623, 2005.","journal-title":"Structure"},{"key":"280_CR28","first-page":"1015","volume":"46","author":"AS Goustin","year":"1986","unstructured":"Goustin, A. S., E. B. Leof, G. D. Shipley, and H. L. Moses. Growth factors and cancer. Cancer Res. 46:1015\u20131029, 1986.","journal-title":"Cancer Res."},{"key":"280_CR29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1126\/science.3498987","volume":"238","author":"L Greenfield","year":"1987","unstructured":"Greenfield, L., V. G. Johnson, and R. J. Youle. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238:536\u2013539, 1987.","journal-title":"Science"},{"key":"280_CR30","doi-asserted-by":"crossref","first-page":"15451","DOI":"10.1021\/bi0518693","volume":"44","author":"PJ Halbrooks","year":"2005","unstructured":"Halbrooks, P. J., A. M. Giannetti, J. S. Klein, P. J. Bjorkman, J. R. Larouche, V. C. Smith, R. T. MacGillivray, S. J. Everse, and A. B. Mason. Composition of pH-sensitive triad in C-lobe of human serum transferrin. Comparison to sequences of ovotransferrin and lactoferrin provides insight into functional differences in iron release. Biochemistry 44:15451\u201315460, 2005.","journal-title":"Biochemistry"},{"key":"280_CR31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/1097-0290(20001020)70:2<225::AID-BIT12>3.0.CO;2-S","volume":"70","author":"JM Haugh","year":"2000","unstructured":"Haugh, J. M., A. Wells, and D. A. Lauffenburger. Mathematical modeling of epidermal growth factor receptor signaling through the phospholipase C pathway: mechanistic insights and predictions for molecular interventions. Biotechnol. Bioeng. 70:225\u2013238, 2000.","journal-title":"Biotechnol. Bioeng."},{"key":"280_CR32","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1016\/j.bmcl.2006.07.076","volume":"16","author":"WA Henne","year":"2006","unstructured":"Henne, W. A., D. D. Doorneweerd, A. R. Hilgenbrink, S. A. Kularatne, and P. S. Low. Synthesis and activity of a folate peptide camptothecin prodrug. Bioorg. Med. Chem. Lett. 16:5350\u20135355, 2006.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"280_CR33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0006-291X(84)91589-4","volume":"124","author":"HR Herschman","year":"1984","unstructured":"Herschman, H. R. The role of binding ligand in toxic hybrid proteins: a comparison of EGF-ricin, EGF-ricin A-chain, and ricin. Biochem. Biophys. Res. Commun. 124:551\u2013557, 1984.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"280_CR34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1083\/jcb.201002119","volume":"190","author":"MT Howes","year":"2010","unstructured":"Howes, M. T., M. Kirkham, J. Riches, K. Cortese, P. J. Walser, F. Simpson, M. M. Hill, A. Jones, R. Lundmark, M. R. Lindsay, D. J. Hernandez-Deviez, G. Hadzic, A. McCluskey, R. Bashir, L. Liu, P. Pilch, H. McMahon, P. J. Robinson, J. F. Hancock, S. Mayor, and R. G. Parton. Clathrin-independent carriers form a high capacity endocytic sorting system at the leading edge of migrating cells. J. Cell Biol. 190:675\u2013691, 2010.","journal-title":"J. Cell Biol."},{"key":"280_CR35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N","volume":"92","author":"SR Husain","year":"2001","unstructured":"Husain, S. R., B. H. Joshi, and R. K. Puri. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer 92:168\u2013175, 2001.","journal-title":"Int. J. Cancer"},{"key":"280_CR36","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1182\/blood.V95.11.3506","volume":"95","author":"SR Husain","year":"2000","unstructured":"Husain, S. R., and R. K. Puri. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi\u2019s sarcoma xenograft. Blood 95:3506\u20133513, 2000.","journal-title":"Blood"},{"key":"280_CR37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1026242432647","volume":"65","author":"SR Husain","year":"2003","unstructured":"Husain, S. R., and R. K. Puri. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol. 65:37\u201348, 2003.","journal-title":"J. Neurooncol."},{"key":"280_CR38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal, A., R. Siegel, J. Xu, and E. Ward. Cancer statistics, 2010. CA Cancer J. Clin. 60:277\u2013300, 2010.","journal-title":"CA Cancer J. Clin."},{"key":"280_CR39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0083-6729(06)74019-5","volume":"74","author":"BH Joshi","year":"2006","unstructured":"Joshi, B. H., C. Hogaboam, P. Dover, S. R. Husain, and R. K. Puri. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam. Horm. 74:479\u2013504, 2006.","journal-title":"Vitam. Horm."},{"key":"280_CR40","first-page":"1948","volume":"8","author":"BH Joshi","year":"2002","unstructured":"Joshi, B. H., K. Kawakami, P. Leland, and R. K. Puri. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin. Cancer Res. 8:1948\u20131956, 2002.","journal-title":"Clin. Cancer Res."},{"key":"280_CR41","first-page":"1168","volume":"60","author":"BH Joshi","year":"2000","unstructured":"Joshi, B. H., G. E. Plautz, and R. K. Puri. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 60:1168\u20131172, 2000.","journal-title":"Cancer Res."},{"key":"280_CR42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/imt.09.8","volume":"1","author":"BH Joshi","year":"2009","unstructured":"Joshi, B. H., and R. K. Puri. IL-13 receptor-alpha2: a novel target for cancer therapy. Immunotherapy 1:321\u2013327, 2009.","journal-title":"Immunotherapy"},{"key":"280_CR43","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.addr.2004.01.002","volume":"56","author":"BA Kamen","year":"2004","unstructured":"Kamen, B. A., and A. K. Smith. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv. Drug Deliv. Rev. 56:1085\u20131097, 2004.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"280_CR44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1073\/pnas.79.2.485","volume":"79","author":"PL Kaplan","year":"1982","unstructured":"Kaplan, P. L., M. Anderson, and B. Ozanne. Transforming growth factor(s) production enables cells to grow in the absence of serum: an autocrine system. Proc. Natl. Acad. Sci. USA 79:485\u2013489, 1982.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"280_CR45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1615\/CritRevImmunol.v21.i1-3.200","volume":"21","author":"K Kawakami","year":"2001","unstructured":"Kawakami, K., M. Kawakami, and R. K. Puri. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit. Rev. Immunol. 21:299\u2013310, 2001.","journal-title":"Crit. Rev. Immunol."},{"key":"280_CR46","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00262-001-0242-6","volume":"50","author":"M Kawakami","year":"2002","unstructured":"Kawakami, M., K. Kawakami, and R. K. Puri. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells. Cancer Immunol. Immunother. 50:691\u2013700, 2002.","journal-title":"Cancer Immunol. Immunother."},{"key":"280_CR47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ijc.10778","volume":"103","author":"M Kawakami","year":"2003","unstructured":"Kawakami, M., K. Kawakami, and R. K. Puri. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways. Int. J. Cancer 103:45\u201352, 2003.","journal-title":"Int. J. Cancer"},{"key":"280_CR48","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood.V97.9.2673","volume":"97","author":"K Kawakami","year":"2001","unstructured":"Kawakami, K., J. Taguchi, T. Murata, and R. K. Puri. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97:2673\u20132679, 2001.","journal-title":"Blood"},{"key":"280_CR49","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1126\/science.1085458","volume":"300","author":"AE Kelly-Welch","year":"2003","unstructured":"Kelly-Welch, A. E., E. M. Hanson, M. R. Boothby, and A. D. Keegan. Interleukin-4 and interleukin-13 signaling connections maps. Science 300:1527\u20131528, 2003.","journal-title":"Science"},{"key":"280_CR50","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/cncr.22134","volume":"107","author":"M Kioi","year":"2006","unstructured":"Kioi, M., M. Kawakami, T. Shimamura, S. R. Husain, and R. K. Puri. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 107:1407\u20131418, 2006.","journal-title":"Cancer"},{"key":"280_CR51","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/ijc.24067","volume":"124","author":"M Kioi","year":"2009","unstructured":"Kioi, M., T. Shimamura, H. Nakashima, M. Hirota, I. Tohnai, S. R. Husain, and R. K. Puri. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int. J. Cancer 124:1440\u20131448, 2009.","journal-title":"Int. J. Cancer"},{"key":"280_CR52","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1016\/S0021-9258(18)32481-5","volume":"258","author":"RD Klausner","year":"1983","unstructured":"Klausner, R. D., J. Van Renswoude, G. Ashwell, C. Kempf, A. N. Schechter, A. Dean, and K. R. Bridges. Receptor-mediated endocytosis of transferrin in K562 cells. J. Biol. Chem. 258:4715\u20134724, 1983.","journal-title":"J. Biol. Chem."},{"key":"280_CR53","first-page":"4741","volume":"53","author":"MS Kobrin","year":"1993","unstructured":"Kobrin, M. S., Y. Yamanaka, H. Friess, M. E. Lopez, and M. Korc. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res. 53:4741\u20134744, 1993.","journal-title":"Cancer Res."},{"key":"280_CR54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1741-7007-4-13","volume":"4","author":"M Kraich","year":"2006","unstructured":"Kraich, M., M. Klein, E. Patino, H. Harrer, J. Nickel, W. Sebald, and T. D. Mueller. A modular interface of IL-4 allows for scalable affinity without affecting specificity for the IL-4 receptor. BMC Biol. 4:13, 2006.","journal-title":"BMC Biol."},{"key":"280_CR55","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/js970246a","volume":"87","author":"F Kratz","year":"1998","unstructured":"Kratz, F., U. Beyer, T. Roth, N. Tarasova, P. Collery, F. Lechenault, A. Cazabat, P. Schumacher, C. Unger, and U. Falken. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci. 87:338\u2013346, 1998.","journal-title":"J. Pharm. Sci."},{"key":"280_CR56","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/neuonc\/nop054","volume":"12","author":"S Kunwar","year":"2010","unstructured":"Kunwar, S., S. Chang, M. Westphal, M. Vogelbaum, J. Sampson, G. Barnett, M. Shaffrey, Z. Ram, J. Piepmeier, M. Prados, D. Croteau, C. Pedain, P. Leland, S. R. Husain, B. H. Joshi, and R. K. Puri. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 12:871\u2013881, 2010.","journal-title":"Neuro Oncol."},{"key":"280_CR57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0006-3495(99)76879-7","volume":"77","author":"VA Kuznetsov","year":"1999","unstructured":"Kuznetsov, V. A., and R. K. Puri. Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: suppression of IL-13 binding by IL-2 receptor gamma chain. Biophys. J. 77:154\u2013172, 1999.","journal-title":"Biophys. J."},{"key":"280_CR58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/bp070080b","volume":"24","author":"BJ Lao","year":"2008","unstructured":"Lao, B. J., and D. T. Kamei. Improving therapeutic properties of protein drugs through alteration of intracellular trafficking pathways. Biotechnol. Prog. 24:2\u20137, 2008.","journal-title":"Biotechnol. Prog."},{"key":"280_CR59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jconrel.2006.12.001","volume":"117","author":"BJ Lao","year":"2007","unstructured":"Lao, B. J., W. L. Tsai, F. Mashayekhi, E. A. Pham, A. B. Mason, and D. T. Kamei. Inhibition of transferrin iron release increases in vitro drug carrier efficacy. J. Control Release 117:403\u2013412, 2007.","journal-title":"J. Control Release"},{"key":"280_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2003.10.002","volume":"30","author":"JJ Laskin","year":"2004","unstructured":"Laskin, J. J., and A. B. Sandler. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev. 30:1\u201317, 2004.","journal-title":"Cancer Treat. Rev."},{"key":"280_CR61","doi-asserted-by":"crossref","first-page":"9839","DOI":"10.1158\/0008-5472.CAN-08-2341","volume":"68","author":"CP Leamon","year":"2008","unstructured":"Leamon, C. P., J. A. Reddy, M. Vetzel, R. Dorton, E. Westrick, N. Parker, Y. Wang, and I. Vlahov. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res. 68:9839\u20139844, 2008.","journal-title":"Cancer Res."},{"key":"280_CR62","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/bc049709b","volume":"16","author":"CP Leamon","year":"2005","unstructured":"Leamon, C. P., J. A. Reddy, I. R. Vlahov, M. Vetzel, N. Parker, J. S. Nicoson, L. C. Xu, and E. Westrick. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjug. Chem. 16:803\u2013811, 2005.","journal-title":"Bioconjug. Chem."},{"key":"280_CR63","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/mp070049c","volume":"4","author":"CP Leamon","year":"2007","unstructured":"Leamon, C. P., J. A. Reddy, I. R. Vlahov, E. Westrick, A. Dawson, R. Dorton, M. Vetzel, H. K. Santhapuram, and Y. Wang. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol. Pharm. 4:659\u2013667, 2007.","journal-title":"Mol. Pharm."},{"key":"280_CR64","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/ijc.22853","volume":"121","author":"CP Leamon","year":"2007","unstructured":"Leamon, C. P., J. A. Reddy, I. R. Vlahov, E. Westrick, N. Parker, J. S. Nicoson, and M. Vetzel. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int. J. Cancer 121:1585\u20131592, 2007.","journal-title":"Int. J. Cancer"},{"key":"280_CR65","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/protein\/6.4.433","volume":"6","author":"CH Lee","year":"1993","unstructured":"Lee, C. H., E. C. Lee, S. T. Tsai, H. J. Kung, Y. C. Liu, and J. Hwang. An EGF-pseudomonas exotoxin A recombinant protein with a deletion in toxin binding domain specifically kills EGF receptor bearing cells. Protein Eng. 6:433\u2013440, 1993.","journal-title":"Protein Eng."},{"key":"280_CR66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/protein\/15.5.419","volume":"15","author":"C Li","year":"2002","unstructured":"Li, C., W. A. Hall, N. Jin, D. A. Todhunter, A. Panoskaltsis-Mortari, and D. A. Vallera. Targeting glioblastoma multiforme with an IL-13\/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng. 15:419\u2013427, 2002.","journal-title":"Protein Eng."},{"key":"280_CR67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/med.10008","volume":"22","author":"H Li","year":"2002","unstructured":"Li, H., and Z. M. Qian. Transferrin\/transferrin receptor-mediated drug delivery. Med. Res. Rev. 22:225\u2013250, 2002.","journal-title":"Med. Res. Rev."},{"key":"280_CR68","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0165-6147(02)01989-2","volume":"23","author":"H Li","year":"2002","unstructured":"Li, H., H. Sun, and Z. M. Qian. The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol. Sci. 23:206\u2013209, 2002.","journal-title":"Trends Pharmacol. Sci."},{"key":"280_CR69","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/BF00218456","volume":"43","author":"CW Liao","year":"1995","unstructured":"Liao, C. W., T. H. Hseu, and J. Hwang. A target-specific chimeric toxin composed of epidermal growth factor and Pseudomonas exotoxin A with a deletion in its toxin-binding domain. Appl. Microbiol. Biotechnol. 43:498\u2013507, 1995.","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"280_CR70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cbpa.2009.03.022","volume":"13","author":"PS Low","year":"2009","unstructured":"Low, P. S., and S. A. Kularatne. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol. 13:256\u2013262, 2009.","journal-title":"Curr. Opin. Chem. Biol."},{"key":"280_CR71","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00262-002-0266-6","volume":"51","author":"Y Lu","year":"2002","unstructured":"Lu, Y., and P. S. Low. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 51:153\u2013162, 2002.","journal-title":"Cancer Immunol. Immunother."},{"key":"280_CR72","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ijc.21126","volume":"116","author":"Y Lu","year":"2005","unstructured":"Lu, Y., E. Sega, and P. S. Low. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int. J. Cancer 116:710\u2013719, 2005.","journal-title":"Int. J. Cancer"},{"key":"280_CR73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10555-007-9046-2","volume":"26","author":"LH Matherly","year":"2007","unstructured":"Matherly, L. H., Z. Hou, and Y. Deng. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev. 26:111\u2013128, 2007.","journal-title":"Cancer Metastasis Rev."},{"key":"280_CR74","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1200\/JCO.2002.20.1.1","volume":"20","author":"J Mendelsohn","year":"2002","unstructured":"Mendelsohn, J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20:1S\u201313S, 2002.","journal-title":"J. Clin. Oncol."},{"key":"280_CR75","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-5793(96)01462-7","volume":"401","author":"B Miloux","year":"1997","unstructured":"Miloux, B., P. Laurent, O. Bonnin, J. Lupker, D. Caput, N. Vita, and P. Ferrara. Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4\/IL-13 receptor complex. FEBS Lett. 401:163\u2013166, 1997.","journal-title":"FEBS Lett."},{"key":"280_CR76","unstructured":"Minino, A. M., J. Xu, K. D. Kochanek, and B. Tejada-Vera. Death in the United States, 2007. NCHS Data Brief 1\u20138, 2009."},{"key":"280_CR77","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/362248a0","volume":"362","author":"A Minty","year":"1993","unstructured":"Minty, A., P. Chalon, J. M. Derocq, X. Dumont, J. C. Guillemot, M. Kaghad, C. Labit, P. Leplatois, P. Liauzun, B. Miloux, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248\u2013250, 1993.","journal-title":"Nature"},{"key":"280_CR78","first-page":"2807","volume":"38","author":"HL Moses","year":"1978","unstructured":"Moses, H. L., J. A. Proper, M. E. Volkenant, D. J. Wells, and M. J. Getz. Mechanism of growth arrest of chemically transformed cells in culture. Cancer Res. 38:2807\u20132812, 1978.","journal-title":"Cancer Res."},{"key":"280_CR79","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.4049\/jimmunol.156.8.2972","volume":"156","author":"T Murata","year":"1996","unstructured":"Murata, T., P. D. Noguchi, and R. K. Puri. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J. Immunol. 156:2972\u20132978, 1996.","journal-title":"J. Immunol."},{"key":"280_CR80","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/bbrc.1997.7248","volume":"238","author":"T Murata","year":"1997","unstructured":"Murata, T., N. I. Obiri, W. Debinski, and R. K. Puri. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem. Biophys. Res. Commun. 238:90\u201394, 1997.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"280_CR81","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0092-8674(92)90623-K","volume":"69","author":"JG Naglich","year":"1992","unstructured":"Naglich, J. G., J. E. Metherall, D. W. Russell, and L. Eidels. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69:1051\u20131061, 1992.","journal-title":"Cell"},{"key":"280_CR82","doi-asserted-by":"crossref","first-page":"15157","DOI":"10.1016\/S0021-9258(19)84801-9","volume":"264","author":"I Pastan","year":"1989","unstructured":"Pastan, I., and D. FitzGerald. Pseudomonas exotoxin: chimeric toxins. J. Biol. Chem. 264:15157\u201315160, 1989.","journal-title":"J. Biol. Chem."},{"key":"280_CR83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1535-6108(03)00089-8","volume":"3","author":"K Pietras","year":"2003","unstructured":"Pietras, K., T. Sjoblom, K. Rubin, C. H. Heldin, and A. Ostman. PDGF receptors as cancer drug targets. Cancer Cell 3:439\u2013443, 2003.","journal-title":"Cancer Cell"},{"key":"280_CR84","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1357-2725(99)00070-9","volume":"31","author":"P Ponka","year":"1999","unstructured":"Ponka, P., and C. N. Lok. The transferrin receptor: role in health and disease. Int. J. Biochem. Cell Biol. 31:1111\u20131137, 1999.","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"280_CR85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/019262339902700111","volume":"27","author":"RK Puri","year":"1999","unstructured":"Puri, R. K. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. Toxicol. Pathol. 27:53\u201357, 1999.","journal-title":"Toxicol. Pathol."},{"key":"280_CR86","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nbt1064","volume":"23","author":"BM Rao","year":"2005","unstructured":"Rao, B. M., D. A. Lauffenburger, and K. D. Wittrup. Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat. Biotechnol. 23:191\u2013194, 2005.","journal-title":"Nat. Biotechnol."},{"key":"280_CR87","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3171\/jns.1990.72.6.0941","volume":"72","author":"L Recht","year":"1990","unstructured":"Recht, L., C. O. Torres, T. W. Smith, V. Raso, and T. W. Griffin. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J. Neurosurg. 72:941\u2013945, 1990.","journal-title":"J. Neurosurg."},{"key":"280_CR88","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/mp900086w","volume":"6","author":"JA Reddy","year":"2009","unstructured":"Reddy, J. A., R. Dorton, A. Dawson, M. Vetzel, N. Parker, J. S. Nicoson, E. Westrick, P. J. Klein, Y. Wang, I. R. Vlahov, and C. P. Leamon. In vivo structural activity and optimization studies of folate-tubulysin conjugates. Mol. Pharm. 6:1518\u20131525, 2009.","journal-title":"Mol. Pharm."},{"key":"280_CR89","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-07-0033","volume":"67","author":"JA Reddy","year":"2007","unstructured":"Reddy, J. A., R. Dorton, E. Westrick, A. Dawson, T. Smith, L. C. Xu, M. Vetzel, P. Kleindl, I. R. Vlahov, and C. P. Leamon. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 67:4434\u20134442, 2007.","journal-title":"Cancer Res."},{"key":"280_CR90","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF02523222","volume":"36","author":"CC Reddy","year":"1998","unstructured":"Reddy, C. C., A. Wells, and D. A. Lauffenburger. Comparative mitogenic potencies of EGF and TGF alpha and their dependence on receptor-limitation versus ligand-limitation. Med. Biol. Eng. Comput. 36:499\u2013507, 1998.","journal-title":"Med. Biol. Eng. Comput."},{"key":"280_CR91","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1158\/0008-5472.CAN-06-3894","volume":"67","author":"JA Reddy","year":"2007","unstructured":"Reddy, J. A., E. Westrick, H. K. Santhapuram, S. J. Howard, M. L. Miller, M. Vetzel, I. Vlahov, R. V. Chari, V. S. Goldmacher, and C. P. Leamon. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res. 67:6376\u20136382, 2007.","journal-title":"Cancer Res."},{"key":"280_CR92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/107327480701400313","volume":"14","author":"CM Rocha-Lima","year":"2007","unstructured":"Rocha-Lima, C. M., H. P. Soares, L. E. Raez, and R. Singal. EGFR targeting of solid tumors. Cancer Control 14:295\u2013304, 2007.","journal-title":"Cancer Control"},{"key":"280_CR93","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/ijc.21647","volume":"118","author":"E Rustamzadeh","year":"2006","unstructured":"Rustamzadeh, E., W. A. Hall, D. A. Todhunter, W. C. Low, H. Liu, A. Panoskaltsis-Mortari, and D. A. Vallera. Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. Int. J. Cancer 118:2594\u20132601, 2006.","journal-title":"Int. J. Cancer"},{"key":"280_CR94","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-005-9051-7","volume":"77","author":"E Rustamzadeh","year":"2006","unstructured":"Rustamzadeh, E., D. A. Vallera, D. A. Todhunter, W. C. Low, A. Panoskaltsis-Mortari, and W. A. Hall. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. J. Neurooncol. 77:257\u2013266, 2006.","journal-title":"J. Neurooncol."},{"key":"280_CR95","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.addr.2004.01.010","volume":"56","author":"S Sabharanjak","year":"2004","unstructured":"Sabharanjak, S., and S. Mayor. Folate receptor endocytosis and trafficking. Adv. Drug Deliv. Rev. 56:1099\u20131109, 2004.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"280_CR96","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-007-9048-0","volume":"26","author":"MD Salazar","year":"2007","unstructured":"Salazar, M. D., and M. Ratnam. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 26:141\u2013152, 2007.","journal-title":"Cancer Metastasis Rev."},{"key":"280_CR97","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1215\/15228517-2008-012","volume":"10","author":"JH Sampson","year":"2008","unstructured":"Sampson, J. H., G. Akabani, G. E. Archer, M. S. Berger, R. E. Coleman, A. H. Friedman, H. S. Friedman, K. Greer, J. E. Herndon, 2nd, S. Kunwar, R. E. McLendon, A. Paolino, N. A. Petry, J. M. Provenzale, D. A. Reardon, T. Z. Wong, M. R. Zalutsky, I. Pastan, and D. D. Bigner. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 10:320\u2013329, 2008.","journal-title":"Neuro Oncol."},{"key":"280_CR98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1026290315809","volume":"65","author":"JH Sampson","year":"2003","unstructured":"Sampson, J. H., G. Akabani, G. E. Archer, D. D. Bigner, M. S. Berger, A. H. Friedman, H. S. Friedman, J. E. Herndon, 2nd, S. Kunwar, S. Marcus, R. E. McLendon, A. Paolino, K. Penne, J. Provenzale, J. Quinn, D. A. Reardon, J. Rich, T. Stenzel, S. Tourt-Uhlig, C. Wikstrand, T. Wong, R. Williams, F. Yuan, M. R. Zalutsky, and I. Pastan. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. 65:27\u201335, 2003.","journal-title":"J. Neurooncol."},{"key":"280_CR99","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/mol.63.1.147","volume":"63","author":"CA Sarkar","year":"2003","unstructured":"Sarkar, C. A., and D. A. Lauffenburger. Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo. Mol. Pharmacol. 63:147\u2013158, 2003.","journal-title":"Mol. Pharmacol."},{"key":"280_CR100","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nbt725","volume":"20","author":"CA Sarkar","year":"2002","unstructured":"Sarkar, C. A., K. Lowenhaupt, T. Horan, T. C. Boone, B. Tidor, and D. A. Lauffenburger. Rational cytokine design for increased lifetime and enhanced potency using pH-activated \u201chistidine switching\u201d. Nat. Biotechnol. 20:908\u2013913, 2002.","journal-title":"Nat. Biotechnol."},{"key":"280_CR101","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","volume":"12","author":"M Scaltriti","year":"2006","unstructured":"Scaltriti, M., and J. Baselga. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 12:5268\u20135272, 2006.","journal-title":"Clin. Cancer Res."},{"key":"280_CR102","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/jcp.21635","volume":"218","author":"MR Schneider","year":"2009","unstructured":"Schneider, M. R., and E. Wolf. The epidermal growth factor receptor ligands at a glance. J. Cell. Physiol. 218:460\u2013466, 2009.","journal-title":"J. Cell. Physiol."},{"key":"280_CR103","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/1535-7163.MCT-05-0543","volume":"5","author":"H Shmeeda","year":"2006","unstructured":"Shmeeda, H., L. Mak, D. Tzemach, P. Astrahan, M. Tarshish, and A. Gabizon. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol. Cancer Ther. 5:818\u2013824, 2006.","journal-title":"Mol. Cancer Ther."},{"key":"280_CR104","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1242\/dev.129.11.2577","volume":"129","author":"SY Shvartsman","year":"2002","unstructured":"Shvartsman, S. Y., C. B. Muratov, and D. A. Lauffenburger. Modeling and computational analysis of EGF receptor-mediated cell communication in Drosophila oogenesis. Development 129:2577\u20132589, 2002.","journal-title":"Development"},{"key":"280_CR105","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1096\/fasebj.3.14.2556314","volume":"3","author":"CB Siegall","year":"1989","unstructured":"Siegall, C. B., Y. H. Xu, V. K. Chaudhary, S. Adhya, D. Fitzgerald, and I. Pastan. Cytotoxic activities of a fusion protein comprised of TGF alpha and Pseudomonas exotoxin. Faseb J. 3:2647\u20132652, 1989.","journal-title":"Faseb J."},{"key":"280_CR106","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0092-8674(82)90163-5","volume":"29","author":"DL Simpson","year":"1982","unstructured":"Simpson, D. L., D. B. Cawley, and H. R. Herschman. Killing of cultured hepatocytes by conjugates of asialofetuin and EGF linked to the A chains of ricin or diphtheria toxin. Cell 29:469\u2013473, 1982.","journal-title":"Cell"},{"key":"280_CR107","first-page":"1423","volume":"18","author":"M Singh","year":"1998","unstructured":"Singh, M., H. Atwal, and R. Micetich. Transferrin directed delivery of adriamycin to human cells. Anticancer Res. 18:1423\u20131427, 1998.","journal-title":"Anticancer Res."},{"key":"280_CR108","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1021\/bp00014a007","volume":"8","author":"C Starbuck","year":"1992","unstructured":"Starbuck, C., and D. A. Lauffenburger. Mathematical model for the effects of epidermal growth factor receptor trafficking dynamics on fibroblast proliferation responses. Biotechnol. Prog. 8:132\u2013143, 1992.","journal-title":"Biotechnol. Prog."},{"key":"280_CR109","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s11882-007-0051-x","volume":"7","author":"Y Tabata","year":"2007","unstructured":"Tabata, Y., and G. K. Hershey. IL-13 receptor isoforms: breaking through the complexity. Curr. Allergy Asthma Rep. 7:338\u2013345, 2007.","journal-title":"Curr. Allergy Asthma Rep."},{"key":"280_CR110","doi-asserted-by":"crossref","first-page":"16872","DOI":"10.1016\/S0021-9258(18)41865-0","volume":"267","author":"CP Theuer","year":"1992","unstructured":"Theuer, C. P., D. FitzGerald, and I. Pastan. A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing. J. Biol. Chem. 267:16872\u201316877, 1992.","journal-title":"J. Biol. Chem."},{"key":"280_CR111","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/gut.2007.137802","volume":"57","author":"DA Vallera","year":"2008","unstructured":"Vallera, D. A., B. J. Stish, Y. Shu, H. Chen, A. Saluja, D. J. Buchsbaum, and S. M. Vickers. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model. Gut 57:634\u2013641, 2008.","journal-title":"Gut"},{"key":"280_CR112","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/cncr.21123","volume":"103","author":"AP Venook","year":"2005","unstructured":"Venook, A. P. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 103:2435\u20132446, 2005.","journal-title":"Cancer"},{"key":"280_CR113","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jcp.1041310314","volume":"131","author":"AM Vollmar","year":"1987","unstructured":"Vollmar, A. M., D. E. Banker, J. Mendelsohn, and H. R. Herschman. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor. J. Cell. Physiol. 131:418\u2013425, 1987.","journal-title":"J. Cell. Physiol."},{"key":"280_CR114","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/bc9500709","volume":"7","author":"S Wang","year":"1996","unstructured":"Wang, S., R. J. Lee, C. J. Mathias, M. A. Green, and P. S. Low. Synthesis, purification, and tumor cell uptake of 67\u00a0Ga-deferoxamine\u2013folate, a potential radiopharmaceutical for tumor imaging. Bioconjug. Chem. 7:56\u201362, 1996.","journal-title":"Bioconjug. Chem."},{"key":"280_CR115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1026246500788","volume":"65","author":"M Weaver","year":"2003","unstructured":"Weaver, M., and D. W. Laske. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. 65:3\u201313, 2003.","journal-title":"J. Neurooncol."},{"key":"280_CR116","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1357-2725(99)00015-1","volume":"31","author":"A Wells","year":"1999","unstructured":"Wells, A. EGF receptor. Int. J. Biochem. Cell Biol. 31:637\u2013643, 1999.","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"280_CR117","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/028418602753669481","volume":"41","author":"A Wells","year":"2002","unstructured":"Wells, A., J. Kassis, J. Solava, T. Turner, and D. A. Lauffenburger. Growth factor-induced cell motility in tumor invasion. Acta Oncol. 41:124\u2013130, 2002.","journal-title":"Acta Oncol."},{"key":"280_CR118","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/(SICI)1097-0290(19980220)57:4<484::AID-BIT13>3.0.CO;2-C","volume":"57","author":"LA Wenning","year":"1998","unstructured":"Wenning, L. A., P. T. Yazdi, and R. M. Murphy. Quantitative analysis of protein synthesis inhibition and recovery in CRM107 immunotoxin-treated HeLa cells. Biotechnol. Bioeng. 57:484\u2013496, 1998.","journal-title":"Biotechnol. Bioeng."},{"key":"280_CR119","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1600-0854.2001.020103.x","volume":"2","author":"HS Wiley","year":"2001","unstructured":"Wiley, H. S., and P. M. Burke. Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic 2:12\u201318, 2001.","journal-title":"Traffic"},{"key":"280_CR120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0962-8924(02)00009-0","volume":"13","author":"HS Wiley","year":"2003","unstructured":"Wiley, H. S., S. Y. Shvartsman, and D. A. Lauffenburger. Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol. 13:43\u201350, 2003.","journal-title":"Trends Cell Biol."},{"key":"280_CR121","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1021\/jm100509v","volume":"53","author":"W Xia","year":"2010","unstructured":"Xia, W., and P. S. Low. Folate-targeted therapies for cancer. J. Med. Chem. 53:6811\u20136824, 2010.","journal-title":"J. Med. Chem."},{"key":"280_CR122","doi-asserted-by":"crossref","first-page":"13872","DOI":"10.1073\/pnas.0601455103","volume":"103","author":"J Yang","year":"2006","unstructured":"Yang, J., H. Chen, I. R. Vlahov, J. X. Cheng, and P. S. Low. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc. Natl. Acad. Sci. USA 103:13872\u201313877, 2006.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"280_CR123","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.106.117648","volume":"321","author":"J Yang","year":"2007","unstructured":"Yang, J., H. Chen, I. R. Vlahov, J. X. Cheng, and P. S. Low. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J. Pharmacol. Exp. Ther. 321:462\u2013468, 2007.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"280_CR124","first-page":"6387","volume":"54","author":"PT Yazdi","year":"1994","unstructured":"Yazdi, P. T., and R. M. Murphy. Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates. Cancer Res. 54:6387\u20136394, 1994.","journal-title":"Cancer Res."},{"key":"280_CR125","first-page":"3763","volume":"55","author":"PT Yazdi","year":"1995","unstructured":"Yazdi, P. T., L. A. Wenning, and R. M. Murphy. Influence of cellular trafficking on protein synthesis inhibition of immunotoxins directed against the transferrin receptor. Cancer Res. 55:3763\u20133771, 1995.","journal-title":"Cancer Res."},{"key":"280_CR126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0090-1229(84)90037-0","volume":"32","author":"CJ Yeh","year":"1984","unstructured":"Yeh, C. J., and W. P. Faulk. Killing of human tumor cells in culture with adriamycin conjugates of human transferrin. Clin. Immunol. Immunopathol. 32:1\u201311, 1984.","journal-title":"Clin. Immunol. Immunopathol."},{"key":"280_CR127","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jconrel.2008.10.006","volume":"133","author":"DJ Yoon","year":"2009","unstructured":"Yoon, D. J., D. S. Chu, C. W. Ng, E. A. Pham, A. B. Mason, D. M. Hudson, V. C. Smith, R. T. MacGillivray, and D. T. Kamei. Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J. Control Release 133:178\u2013184, 2009.","journal-title":"J. Control Release"},{"key":"280_CR128","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/0008-5472.CAN-09-4311","volume":"70","author":"DJ Yoon","year":"2010","unstructured":"Yoon, D. J., B. H. Kwan, F. C. Chao, T. P. Nicolaides, J. J. Phillips, G. Y. Lam, A. B. Mason, W. A. Weiss, and D. T. Kamei. Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Res. 70:4520\u20134527, 2010.","journal-title":"Cancer Res."},{"key":"280_CR129","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1074\/jbc.M807665200","volume":"284","author":"R Zhao","year":"2009","unstructured":"Zhao, R., S. H. Min, Y. Wang, E. Campanella, P. S. Low, and I. D. Goldman. A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J. Biol. Chem. 284:4267\u20134274, 2009.","journal-title":"J. Biol. Chem."},{"key":"280_CR130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0167-5699(94)90021-3","volume":"15","author":"G Zurawski","year":"1994","unstructured":"Zurawski, G., and J. E. de Vries. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today 15:19\u201326, 1994.","journal-title":"Immunol. Today"}],"container-title":["Annals of Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10439-011-0280-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T11:21:02Z","timestamp":1685964062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10439-011-0280-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,25]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1007\/s10439-011-0280-y","relation":{},"ISSN":["0090-6964","1573-9686"],"issn-type":[{"value":"0090-6964","type":"print"},{"value":"1573-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,25]]}}}